Key Drivers
- Profitability reversal
- Cash burn
- Negative equity
AIAI Summary
NVAX is shifting from a pure cash-burn story to a partnership-driven turnaround, but the investment case only improves if Sanofi/Matrix-M milestones and deferred revenue convert into repeatable operating cash flow before persistent negative FCF, negative equity, and margin erosion create a financing overhang.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability reversal
- •Cash burn
- •Negative equity
NVAX's latest quarter showed a sharp profitability and cash-flow reversal despite solid liquidity and deferred revenue, making the stock look cheap but still highly risky.
Price Behavior
Key Price Behavior Insights:
- •Rebound momentum
- •Range-bound trading
- •Resistance overhead
NVAX has improved over the last month after a mid-June selloff, but it remains range-bound with support at $8.56-$8.90 and resistance near $10.20-$10.51 until it clears $10.20.
Rebounded from $8.56 to $9.74 after a mid-June selloff
Sentiment & News
Key News Insights:
- •Investor attention
- •Trading volatility
- •Shareholder dissent
Novavax is drawing heightened attention amid volatile trading, sector scrutiny, and shareholder dissent, but recent moves appear driven more by sentiment than by a clear business catalyst.
The stock may remain choppy in the near term as governance concerns and mixed trading signals keep sentiment uncertain
Similar Companies in Healthcare
Other companies in the same sector with AI ratings